Peter Andersen Email & Phone Number
@vita-therapeutics.com
LinkedIn matched
Who is Peter Andersen? Overview
A concise factual answer block for searchers comparing this professional profile.
Peter Andersen is listed as Chief Research and Development Officer at TreeFrog Therapeutics, a with 178 employees, based in United States. AeroLeads shows a work email signal at vita-therapeutics.com and a matched LinkedIn profile for Peter Andersen.
Peter Andersen previously worked as Chief Research & Development Officer at Treefrog Therapeutics and Member Board of Directors at Jellatech. Peter Andersen holds Phd, Molecular Biology from Københavns Universitet - University Of Copenhagen.
Email format at TreeFrog Therapeutics
This section adds company-level context without repeating Peter Andersen's masked contact details.
AeroLeads found 1 current-domain work email signal for Peter Andersen. Compare company email patterns before reaching out.
About Peter Andersen
Executive leadership, Entrepreneur, Founder, Investor, Start-up advisor, Board member, Keynote Speaker, Demonstrated history of working in the academic and biomedical industry. Expertise in regenerative medicine, cell & gene therapy.
Listed skills include Cell, Molecular Biology, Cancer, Cell Biology, and 42 others.
Peter Andersen's current company
Company context helps verify the profile and gives searchers a useful next step.
Peter Andersen work experience
A career timeline built from the work history available for this profile.
Chief Research & Development Officer
Current
Member Board Of Directors
Current
Adjunct Professor
CurrentHeart and muscle development and disease, iPSC-based disease modeling, cell and gene therapies.
Assistant Professor
Research focused on understanding the mechanisms of heart & muscle development and disease by deciphering the molecular and cellular mechanisms that regulate differentiation, specification, and pathogenesis, with a specific focus on studying the main concepts of embryology and how undifferentiated cells interpret signals from extra-cellular stimuli and undergo differentiation to somatic linages. Combining genomic approaches with high content imaging platforms to study multicellular events in complex tissue at a single-cell resolution, while using pluripotent stem cells and mice as primary model systems to establish disease models for in vitro/vivo validation of targeted compounds and cell-based therapies.Specialties: Cell therapy, gene therapy, gene-editing, heart development and disease, cancer biology, genetic and molecular diagnostics, drug discovery, pharmacology, pluripotent stem cells and 3D cell engineering.Publications, patents, funding history: https://orcid.org/0000-0003-3971-0467
Director, Jhu Stem Cell Program
Standardization and manufacturing of high quality Induced Pluripotent Stem Cells from patients for disease modeling and drug discovery
Executive Board Member, Johns Hopkins Biotech Investment Group (Jhbig)
Founding member of the Johns Hopkins Biotech Investment Group
Founder And Organizer, Jhu Stem Cell Consortium
JHU Stem Cell Consortium is a collaborative network of scientific researchers in the field of stem cell biology and cell engineering at Johns Hopkins University.
Co-Founder
Current
Investor And Member Of The Byfounders Collective
CurrentbyFounders is an early stage venture fund actively investing in tech startups across the Nordics and Baltics. Made up of some of the region's most accomplished entrepreneurs, the byFounders Collective invests and supports the next generation of globally ambitious founders - it's "for founders, byFounders"
Guest Lecturer
Business Student
Equity Research Analyst
Postdoctoral Research Fellow
Publications:1. Chelko SP, Asimaki A, Andersen P., et al. Central role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy.2. Morita Y, Andersen P., et al. Sall1 transiently marks undifferentiated heart precursors and regulates their fate. 2016, J Mol Cell Cardiol.3. Andersen P & Kwon C. Ex Vivo Culture of Pharyngeal Arches to Study Heart and Muscle Progenitors and Their Niche, 2015, J. Vis Exp.4. Shenje L & Andersen P., et al, Precardiac deletion of Numb and Numblike reveals renewal of cardiac progenitors. 2014, eLife.5. Shenje L & Andersen P., et al. Mutations in Alström protein impair terminal differentiation of cardiomyocytes. 2014, Nature Communications.6. Uosaki H & Andersen P., et al. Direct contact with endoderm-like cells efficiently induces cardiac progenitors from mouse and human pluripotent stem cells. 2012, Plos One.7. Andersen et al., Non-canonical Notch signaling: emerging role and mechanism. 2012, Trends in Cell Biology.
Visiting Researcher
Heart development and diseasePublications:1. Cheng P & Andersen P., et al. Fibronectin mediates mesendodermal cell fate decisions. 2013, Development.2. Kwon C, Cheng P, King IN, Andersen P, et al. Notch Post-Translationally Regulates b-Catenin Protein in Stem and Progenitor Cells. 2011, Nature Cell Biology.
Phd Candidate
Cardiac development and regenerative stem cell therapy. Thesis entitled: Induction and characterization of cardiac progenitors.Publications: 1. Andersen P., et al. Shaping the Herat in Development and Disease; MicroRNA in heart development and disease. 2010, Research Signpost.2. Andersen D & Andersen P., et al. Murine "cardiospheres" are not a source of stem cells with cardiomyogenic potential. 2009, Stem Cells.
Researcher, Department Of Radiation Biology
Research with focus on signal transduction downstream of EGFR/EGFRvIII in human cancer, and modulation of gene therapy particles for treatment of small cell lung cancer (SCLC).1. Andersen P., et al. Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells. 2009, Cancer Investigation.2. Andersen P., et al. EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. 2008, International Journal of Cancer.3. Zandi R., et al. Mechanisms for oncogenic activation of the epidermal growth factor receptor. 2007, Cell Signalling
Master Student, Department Of Radiation Biology
Master studies: Masters Thesis entitled: ’Role of the tumor suppressor IRF-1 activated by the epidermal growth factor receptor in human cancer cells’
Colleagues at TreeFrog Therapeutics
Other employees you can reach at treefrog.fr. View company contacts for 178 employees →
Jurgen Biesemans
Colleague at Treefrog TherapeuticsGreater Bordeaux Metropolitan Area, France
View →
BG
Basile Gurchenkov
Colleague at Treefrog TherapeuticsParis, Île-De-France, France
View →
LC
Louis Cance
Colleague at Treefrog TherapeuticsMérignac, Nouvelle-Aquitaine, France
View →
MR
Maxime Renvoisé
Colleague at Treefrog TherapeuticsBeautiran, Nouvelle-Aquitaine, France
View →
PF
Pauline François
Colleague at Treefrog TherapeuticsGreater Marseille Metropolitan Area, France
View →
HR
Hélène Riesterer
Colleague at Treefrog TherapeuticsNouvelle-Aquitaine, France
View →
SG
Solenn Guilbert
Colleague at Treefrog TherapeuticsFrance
View →
GD
Guillaume Dabée
Colleague at Treefrog TherapeuticsBordeaux, Nouvelle-Aquitaine, France
View →
JC
Jessica Colombo
Colleague at Treefrog TherapeuticsBordeaux, Nouvelle-Aquitaine, France
View →
AF
Amélie Ferreboeuf
Colleague at Treefrog TherapeuticsBordeaux, Nouvelle-Aquitaine, France
View →
Peter Andersen education
Phd, Molecular Biology
Phd, Cardiac Development
Msc, Biology
Bsc, Biology, General
Frequently asked questions about Peter Andersen
Quick answers generated from the profile data available on this page.
What company does Peter Andersen work for?
Peter Andersen works for TreeFrog Therapeutics.
What is Peter Andersen's role at TreeFrog Therapeutics?
Peter Andersen is listed as Chief Research and Development Officer at TreeFrog Therapeutics.
What is Peter Andersen's email address?
AeroLeads has found 1 work email signal at @vita-therapeutics.com for Peter Andersen at TreeFrog Therapeutics.
Where is Peter Andersen based?
Peter Andersen is based in United States while working with TreeFrog Therapeutics.
What companies has Peter Andersen worked for?
Peter Andersen has worked for Treefrog Therapeutics, Jellatech, The Johns Hopkins University School Of Medicine, Vita Therapeutics, and Byfounders.
Who are Peter Andersen's colleagues at TreeFrog Therapeutics?
Peter Andersen's colleagues at TreeFrog Therapeutics include Jurgen Biesemans, Basile Gurchenkov, Louis Cance, Maxime Renvoisé, and Pauline François.
How can I contact Peter Andersen?
You can use AeroLeads to view verified contact signals for Peter Andersen at TreeFrog Therapeutics, including work email, phone, and LinkedIn data when available.
What schools did Peter Andersen attend?
Peter Andersen holds Phd, Molecular Biology from Københavns Universitet - University Of Copenhagen.
What skills is Peter Andersen known for?
Peter Andersen is listed with skills including Cell, Molecular Biology, Cancer, Cell Biology, Cell Culture, Pcr, Qpcr, and Biotechnology.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial